Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

688
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
688
X-linked Traits01:19

X-linked Traits

53.1K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
53.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

3.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.6K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

37
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
37

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The hunt for a cure: modern medical approaches for immune thrombocytopenia.

Expert review of hematology·2026
Same author

Popping FVIII concentrates into an updated classification.

Blood advances·2026
Same author

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.

British journal of haematology·2026
Same author

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation.

American journal of hematology·2025
Same author

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Blood·2025
Same author

Immigration Enforcement Tactics and Systemic Health Harms: The Ethical Imperative for Medical Advocacy.

Annals of internal medicine·2025

Related Experiment Video

Updated: May 29, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K

2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders.

Debbie Jiang1, Michael Wang2, Allison P Wheeler3

  • 1Hematology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.

American Journal of Hematology
|February 4, 2025
PubMed
Summary

Innovative treatments for inherited bleeding disorders are expanding to include new patient groups and conditions. Personalized prophylaxis strategies are crucial for optimizing long-term outcomes and safety.

Keywords:
bispecific antibodiesblood coagulation factorsfactor concentrategene therapyrebalancing therapy

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.5K
Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.1K

Related Experiment Videos

Last Updated: May 29, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.5K
Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.1K

Area of Science:

  • Hematology
  • Pharmacology
  • Genetics

Background:

  • Inherited bleeding disorders (IBDs) management is evolving with novel prophylaxis options.
  • Clinical trials are expanding to include non-hemophilia bleeding disorders and diverse demographics (females, children, infants).

Purpose of the Study:

  • To review current clinical trials and preclinical developments in IBD therapeutics.
  • To highlight the expanding landscape of innovative prophylaxis for IBDs.

Main Methods:

  • Review of ongoing clinical trials for IBDs.
  • Assessment of preclinical development in IBD therapeutics.

Main Results:

  • Clinical trials focus on indication expansion, efficacy/safety in new disorders (e.g., von Willebrand disease), and long-term outcomes.
  • Innovative therapies include engineered clotting factors, FVIIIa mimetics, gene therapies, and rebalancing agents.

Conclusions:

  • Treatment for IBDs is shifting towards personalized prophylaxis based on individual needs.
  • A nuanced understanding of novel therapies' mechanisms, benefits, and risks is essential for providers.